author-photo

Mochael W. Deininger

Huntsman Cancer Institute

5

Papers

8

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia (BFORE trial) : 24-month efficacy update and results by 3-month BCR-ABL1 transcript levels

2018 Onkologie
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and Safety of First-Line Bosutinib versus Imatinib in the BFORE trial : 18-Month Follow-up

2018
Show All
- Source
- Cite
- Save
Citations (0)
Bosutinib (BOS) vs imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): initial results from the bfore trial

2017 Onkologie
Show All
- Source
- Cite
- Save
Citations (0)
Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

2015 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

2015 Blood
Show All
- Source
- Cite
- Save
Citations (8)